Compare · NVO vs RNTX
NVO vs RNTX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rein Therapeutics Inc. (RNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2257.0x RNTX ($81.2M).
- Over the past year, NVO is down 45.7% and RNTX is down 50.7% - NVO leads by 5.0 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 5 for RNTX).
- NVO has more recent analyst coverage (25 ratings vs 2 for RNTX).
- Company
- Novo Nordisk A/S
- Rein Therapeutics Inc.
- Price
- $41.01-4.51%
- $0.94-0.31%
- Market cap
- $183.15B
- $81.2M
- 1M return
- -10.44%
- -19.89%
- 1Y return
- -45.66%
- -50.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RNTX
- SEC Form DEFA14A filed by Rein Therapeutics Inc.
- SEC Form DEF 14A filed by Rein Therapeutics Inc.
- Director Von Rickenbach Josef H bought $49,561 worth of Common stock (47,060 units at $1.05), increasing direct ownership by 305% to 62,514 units (SEC Form 4)
- SEC Form PRE 14A filed by Rein Therapeutics Inc.
- Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
- SEC Form 10-Q filed by Rein Therapeutics Inc.
- Officer Windsor James Brian bought $25,000 worth of Common stock (25,000 units at $1.00), increasing direct ownership by 1,222% to 27,046 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Rein Therapeutics Inc.
- SEC Form 8-K filed by Rein Therapeutics Inc.
- SEC Form 424B5 filed by Rein Therapeutics Inc.